does food roughly double how much ziprasidone is absorbed?
“Food can roughly double how much Zipracidone is absorbed.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-28, at 11:13. hear it in context →
the episode: First-Episode Psychosis in Women (at 11:13). we link the show's own page; we do not re-host audio.
first, the part that holds
the claim holds up. the current FDA label for ziprasidone capsules says absorption "is increased up to two-fold in the presence of food," and two manufacturer-run studies we read found exposure with a full meal at about double the fasting level.
what we found when we went and looked
we read the current ziprasidone label through openFDA. it says absorption "is increased up to two-fold in the presence of food," gives the absolute bioavailability of a 20 mg dose with food as about 60%, and tells prescribers to give the capsules with food. in a single-dose crossover study in healthy volunteers, AUC (total drug exposure) was higher with a meal by 48% at 20 mg, 87% at 40 mg and 101% at 80 mg. in a randomized crossover trial in patients already taking the drug, exposure with a 1000 kcal meal was "nearly twice" the fasting level. the speaker's "can roughly double" matches the record, including the hedge. one detail the speaker left out: doubling is the top of the range. it depends on dose and on meal size, and in the patient trial a small (250 kcal) meal gave exposures close to fasting.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| taking ziprasidone with food increases how much of it is absorbed | confirmed | the FDA label says absorption is increased in the presence of food, and both studies found higher AUC fed than fasting at every dose and meal tested. the label does not give an n for this statement, and the studies were small crossover designs. [1][2][3] |
| the increase is roughly two-fold | confirmed | the label says 'up to two-fold.' in the single-dose study the increase was +101% at 80 mg and +100% with a 60%-fat meal at 40 mg. in the steady-state patient trial, exposure with a 1000 kcal meal was 'nearly twice' fasting. 'roughly double' with 'can' matches the label's 'up to.' [1][2][3] |
| the size of the food effect is the same at every dose and with any meal | overstated | this is a reading a listener could take away, not something the speaker said. the increase was +48% at 20 mg and +87% at 40 mg, against +101% at 80 mg. a 250 kcal meal gave exposures that 'approached exposures seen under fasting conditions.' a 500 kcal meal gave exposures similar to 1000 kcal, and fat content made no significant difference. [2][3] |
| with food, about 60% of an oral dose reaches the bloodstream | confirmed | the label says 'the absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%.' this is background for the claim, and the label gives this figure only for the 20 mg dose with food. [1] |
both directions
for the speaker: the FDA label uses nearly the speaker's wording ("up to two-fold"). in the single-dose crossover study, AUC rose 101% at 80 mg, and with a 60%-fat meal at 40 mg it rose 100%. in the patient trial at steady state, exposure with a high-calorie meal was "nearly twice" fasting. the label's instruction to give the capsules with food rests on this effect, and the single-dose study also found less variability between people when the drug was taken with food.
against: nothing in the record contradicts the speaker. what it adds is that doubling is the upper end. at 20 mg the increase was 48%, and at 40 mg it was 87%. meal size matters more than fat content: in the patient trial a 250 kcal meal gave exposures close to fasting, and it took about 500 kcal to get the full effect. so "with food" in practice means a real meal, not a snack. a listener could take away "any food doubles it," and the record does not support that version.
what this cannot say
all the food-effect data we found comes from studies the manufacturer ran or sponsored. they are small crossover studies: 8 healthy men in the dose study, 14 healthy subjects in the fat study, and an n we could not confirm from the patient-trial abstract. the single-dose results are a conference abstract, not a full paper. we read abstracts and the label text, not full datasets or individual-level variability. AUC measures how much drug reaches the blood. it does not show that more absorption means better symptom control or more side effects for any one person. the openFDA record we read did not show a set id, so we could not tie the quote to a specific label version beyond its listed update date. none of this is guidance on how anyone should take their own medication.
sources, each one fetched and read
- U.S. Food and Drug Administration, openFDA drug label API, ziprasidone hydrochloride oral capsules, prescribing information (record updated 2026-10-28) What we read there: "The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%." "The absorption of ziprasidone is increased up to two-fold in the presence of food." Dosing: "Administer capsules orally with food." Fetched 2026-10-29 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"ziprasidone"+AND+openfda.route:"ORAL"&limit=1
- Impact of food on absorption of ziprasidone. European Psychiatry, vol. 22, suppl. S1, March 2007 (conference abstract, manufacturer authors). doi:10.1016/j.eurpsy.2007.01.507 What we read there: 6-way crossover in 8 healthy males: "AUC was greater in fed than fasting states at each dose (20 mg, +48%; 40 mg, +87%; 80 mg, +101%)." In a 14-subject study, "AUC increased by 100% (60%-fat meal) and 80% (30%-fat meal) relative to the fasting state." Fetched 2026-10-29 (HTTP 200). https://www.cambridge.org/core/journals/european-psychiatry/article/impact-of-food-on-absorption-of-ziprasidone/303E217CDC565EAD18B37752C297989E
- The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. Journal of Clinical Psychiatry, 2009;70(1):58-62. PMID 19026256. doi:10.4088/jcp.08m04104 What we read there: In patients already on oral ziprasidone, exposures with high-calorie meals (1000 kcal) "were nearly twice those observed under fasting conditions." 500 kcal meals gave similar exposures. 250 kcal meals were 60% to 90% lower and approached fasting levels. Fat content had no significant effect. Fetched 2026-10-29 (HTTP 200). https://pubmed.ncbi.nlm.nih.gov/19026256/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam